Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022 16:01 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
November 01, 2022 08:00 ET
|
Denali Therapeutics Inc.
Interim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593Single doses of DNL593 were generally...
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 24, 2022 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of...
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
October 19, 2022 21:19 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its...
Denali Therapeutics Announces Proposed Offering of Common Stock
October 18, 2022 16:40 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in...
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
October 03, 2022 08:00 ET
|
Denali Therapeutics Inc.
Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has...
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
August 31, 2022 08:00 ET
|
Denali Therapeutics Inc.
Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable...
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 08, 2022 16:01 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 31, 2022 08:00 ET
|
Denali Therapeutics Inc.
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640...
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 05, 2022 16:01 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...